Expert Point of View: Catherine Bollard, MD


Get Permission

Catherine Bollard, MD

Blinatumomab is one of several approaches to harness the immune system, and these therapies will revolutionize the treatment of cancer.

—Catherine Bollard, MD

Blinatumomab is one of several approaches to harness the immune system, and these therapies will revolutionize the treatment of cancer, but we will have to balance the effects of ‘revving up’ the immune system with toxicity. Compared with CAR [chimeric antigen receptor] T cells [made from each patient’s T cells] genetically engineered to target the CD19 antigen, blinatumomab is an ‘off the shelf” treatment for all patients,” said Catherine Bollard, MD, a bone marrow transplant specialist at Children’s National Hospital and George Washington University, Washington, DC. ■

 


Related Articles

Blinatumomab Achieves Complete Molecular Responses in Majority of B-Cell Leukemia Patients

Results from the international phase II BLAST study show that one cycle of blinatumomab (Blincyto) immunotherapy achieved complete minimal residual disease response in 78% of patients with acute lymphoblastic leukemia.1 Complete minimal residual disease response was achieved in 80% of patients...


Advertisement

Advertisement



Advertisement